Abdul Mannan: Advancing VWF Activity Testing Beyond VWF:RCo in Clinical Laboratories
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“Your VWF activity assay might be giving you the wrong answer.
And that wrong answer changes everything downstream.
VWF:RCo has been the workhorse of VWD testing for decades.
But here’s what the data actually shows:
- VWF:RCo imprecision sits around 9%. GPIb-based assays? Around 3.2%.
- Ristocetin-sensitive polymorphisms can falsely lower the activity:Ag ratio. That’s not biology. That’s assay noise.
- In diverse populations, this creates a predictable disadvantage. The same patient, different ethnicity, different result. That’s an equity problem.
Why does this matter so much?
The VWF activity result sits at the centre of the subtype algorithm. I
f that number drifts, everything drifts with it:
- Type 1 patients get pushed into a Type 2 work-up
- Unnecessary multimers, RIPA, genetics referrals follow
- DDAVP decisions and perioperative plans change
- Borderline cases get missed entirely
VWF:GPIbM offers a way out.
No ristocetin dependence.
No polymorphism distortion.
92% Type 2 sensitivity. 85.1% Type 1 specificity. Same 0.70 activity:Ag ratio threshold. Same diagnostic logic.
The message is simple: modernise the assay, preserve the pathway.
Both BSH 2024 and ASH/ISTH 2021 guidelines point the same direction.
But this isn’t just a reagent swap.
It’s a quality programme.
- Validation
- Reporting language
- Clinical education
- Post-go-live review
All need to land together.
I built an interactive guide to walk laboratories through this transition step by step.
- Assay comparison
- Decision algorithms
- Implementation framework
- Rhe evidence behind each choice
All in one place.
Has your lab made this switch yet?
What held you back, or what pushed you forward?”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS